Who is sponsoring NCT03143543?

NCT03143543 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT03143543?

Interventions in NCT03143543: Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo, Group B2 Parallel Placebo.

What condition does NCT03143543 study?

NCT03143543 studies Cocaine-Related Disorders, Opioid-Related Disorders.

Is NCT03143543 still recruiting?

NCT03143543 is currently terminated. Last updated 23 April 2020.

Last reviewed 2020-04-23 · How we verify

NCT03143543

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

Terminated Phase 1 Last updated 23 April 2020

What this trial tests

Phase 1 trial testing Group A Lorcaserin (10mg) in Cocaine-Related Disorders in 171 participants. Terminated before completion.

Timeline

1 July 2015

Primary endpoint
6 December 2019

6 December 2019

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	171
Start date	1 July 2015
Primary completion	6 December 2019
Estimated completion	6 December 2019
Sites	1 location across United States

Drugs / interventions tested

Group A Lorcaserin (10mg) — full drug profile →
Group A2 Lorcaserin (20 mg) — full drug profile →
Group B Parallel Placebo
Group B2 Parallel Placebo

Conditions studied

Cocaine-Related Disorders — all drugs for Cocaine-Related Disorders →
Opioid-Related Disorders — all drugs for Opioid-Related Disorders →

Sponsor

Virginia Commonwealth University

Who can join

Adults 18 to 55, any sex, with Cocaine-Related Disorders or Opioid-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Target engagement by lorcaserin
Time frame: Seven Days
To determine target engagement by lorcaserin in a cocaine-Stroop and/or opioid-Stroop cue-reactivity fMRI task in cocaine use disorder (CocUD) and/or Opioid Use Disorder Subjects

Sponsor's own description

The purpose of Project 2 is to execute phase I functional magnetic resonance imaging (fMRI) studies to assess the effects of lorcaserin on brain target engagement (measured by fMRI brain activation and neural connectivity) in cocaine use disorder (CocUD) subjects and/or opioid use disorder.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.
Collins GT, Gerak LR, France CP. · · 2018 · cited 27× · PMID 29246856 · DOI 10.1016/j.neuropharm.2017.12.023
Converging vulnerability factors for compulsive food and drug use.
Serafine KM, O'Dell LE, Zorrilla EP. · · 2021 · cited 17× · PMID 33862029 · DOI 10.1016/j.neuropharm.2021.108556
Improving Translational Research Outcomes for Opioid Use Disorder Treatments.
Jones JD, Varshneya NB, Hudzik TJ, Huhn AS. · · 2021 · cited 10× · PMID 37377692 · DOI 10.1007/s40429-020-00353-5

Verify or expand the search:

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03143543 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 23 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03143543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing